Clinical Trial: Becotatug Vedotin in Combination With Immunotherapy and Multimodality Radiotherapy for Esophageal Squamous Cell Carcinoma in the Second-line or Later Setting

U.S., Oct. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07892833) titled 'Becotatug Vedotin in Combination With Immunotherapy and Multimodality Radiotherapy for Esophageal Squamous Cell Carcinoma in the Second-line or Later Setting' on Oct. 16.

Brief Summary: This is a prospective, single-arm, exploratory, single-center clinical study designed to evaluate the efficacy and safety of becotatug vedotin (MRG003) in combination with an investigator's choice of immune checkpoint inhibitor (ICI) plus multimodal radiotherapy in patients with advanced esophageal squamous cell carcinoma (ESCC) in the second-line or later setting.

Treatment regimen for eligible subjects:

Becotatug vedotin (MRG003): 2.0 mg/kg, admi...